Navigation Links
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Date:8/19/2007

with each

of the partners for further pre-clinical or clinical development;

projects without established collaborations will be assessed for

continued development to the next step with or without a partner

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology. These molecules and compounds could be currently available or are in pre-clinical or clinical development. Such molecules or compounds usually cannot be delivered by the oral route of administration or the benefits of these compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The Web site is: http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and c
'/>"/>

SOURCE Emisphere Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes MobileHelp with the 2014 North ... Value Leadership. MobileHelp,s leadership in flexibility across in-home ... progression in personal emergency response, and exemplifies key ... MobileHelp is at the forefront of convenience ...
(Date:7/29/2014)... , July 29, 2014 ... Austria will present data from a Phase ... aims to slow or stop Parkinson,s disease progression. The ... $ 1.5 million grant and will discuss the impact of ... When:   Thursday, July 31, 2014 ...
(Date:7/29/2014)... July 29, 2014   Abide Therapeutics ... to its board of directors. Thornberry was ... and Endocrinology for Merck & Co. Inc., where ... pipeline management in diabetes, osteoporosis, fertility and contraception. ... the program that resulted in the discovery of ...
Breaking Medicine Technology:Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ... Release Formulation, CHICAGO, April ... sustained-release investigational compound to treat,Restless Legs Syndrome (RLS), showed that ... placebo, and was,generally well-tolerated when administered once-daily for 12 weeks., ...
... Expansion of Company,s Phase 3 Study for Wet AMD after ... 90-day Review ... announced,today that the U.S. Food and Drug Administration (FDA) has granted ... Phase 3 trial from 10 to 30 in the United States. ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
(Date:7/29/2014)... (PRWEB) July 30, 2014 Saint ... recently been awarded the Patient-Centered Medical Home 2011 ... National Committee for Quality Assurance. Only one out ... Level I, Level 2, or Level 3 recognition. ... in Patient-Centered Medical Home report faster access to ...
(Date:7/29/2014)... VogueQueen.com, a well-known online supplier, now ... trends in garment fashion by providing graceful and sexy ... an all-inclusive array of sexy dresses , designed ... lot of customers take price into consideration. Worry no ... the purchase more affordable for all clients. , ...
(Date:7/29/2014)... a form of acupuncture where a small ... needles produces significant improvements in fatigue, anxiety ... for early stage breast cancer patients experiencing joint ... (AIs) to treat breast cancer. The results of ... by researchers at the Perelman School of Medicine ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Diabetes is a ... is developed, blood sugar levels are increased, while the production ... produced by the pancreas and which is needed by the ... to overcome and can be very dangerous, as there are ... To learn more about this disorder and read a complex ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica ... new method of naturally overcoming sciatica, in less than ... method ensure sufferers that the cure is simple to ... The new method is described as very fast, as ... an 8 minutes per day treatment plan. , ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... found in foods, study shows , FRIDAY, Aug. 14 ... choline during pregnancy increases the risk of brain and ... focused on two types of neural tube birth defects ... condition in which the brain and skull don,t develop, ...
... named one of the top 10 hospital systems in the ... a leading business and professional information organization based in New ... systems outperformed their peers by a wide margin. They ... more lives, had fewer patient complications, and made fewer patient ...
... , ... On Oct. 9-10, 2009, CRSA will hold ... the organization. An estimated 300 surgeons will be in attendance ... applications for gastrointestinal, colorectal, vascular, transplant, endocrine, oncology and bariatrics. Those ...
... Mich., Aug. 14 Work and economy related stress is taking ... independent survey conducted by American Laser Centers, the largest provider of ... respondents who took part in the survey (47 percent) currently feel ... , , The physical toll of their ...
... /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), ... great progress being made with the experimental findings ... cure of Multiple Sclerosis not only in their ... unauthorized news link) , , http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20090812/mtl_090812/20090812?hub=Health ...
... , , SAN FRANCISCO, Aug. ... few have success rates higher than 50 percent and none have been ... r al H e alth International (NHI), ... today, its Femmenessence line has been clinically proven to alleviate ...
Cached Medicine News:Health News:University Hospitals in Cleveland named one of the top 10 hospital systems in United States 2Health News:International Robotic Surgery Forum Launches In Chicago 2Health News:International Robotic Surgery Forum Launches In Chicago 3Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 2Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 3Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 4Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Medicine Products: